Abstract: To analyze the response rate and security of cladribine in heavily retreated patients with indolent B-cell lymphomas. Methods: Clinical records of 18 cases of indolent B-cell lymphomas treated with a cladribine combined with cyclophosphamide ( CC ) regimen were retrospectively analyzed. Results: Among the 18 patients, 9 were diagnosed as grade 1-2 follicular lymphoma. The median age was 54.5 years, with marked male predominance ( 1.25:1 ). Up to 88.7% of patients were of clinical stages Ⅲ to Ⅳ, 16.7% of patients had B symptoms, 38.9% of patients were with elevated lactate dehydrogenase. Up to 13 patients completed 2 or more cycles of the CC regimen, 5 patients completed only 1 cycle. The response rate was 27.8%, with a complete remission ( CR ) rate of 16.7%. Myelosuppression was the major toxicity with 33.3% of grades 3 and 4 neutropenia. Conclusion: Cladribine used in the heavily retreated patients of indolent B-cell lymphoma shows good efficacy and is safety.